Coumadin

International Normalised Ratio Increased	19.9%
International Normalised Ratio Decreased	12.8%
International Normalised Ratio Fluctuation	11.8%
International Normalised Ratio Abnormal	5.5%
Haemorrhage	5.4%
Drug Ineffective	5.1%
Thrombosis	4.5%
Death	4.4%
Rash	3.4%
Epistaxis	3.3%
Alopecia	3.3%
Subdural Haematoma	3.0%
Gastrointestinal Haemorrhage	2.6%
Pulmonary Embolism	2.4%
Contusion	2.3%
Rectal Haemorrhage	2.3%
Prothrombin Time Prolonged	2.3%
Anaemia	2.0%
Cerebrovascular Accident	1.9%
Adverse Event	1.9%

Secondary

Product Used For Unknown Indication	22.9%
Drug Use For Unknown Indication	20.7%
Atrial Fibrillation	14.1%
Hypertension	5.1%
Deep Vein Thrombosis	4.6%
Anticoagulant Therapy	4.4%
Pulmonary Embolism	3.9%
Peritoneal Dialysis	2.9%
Thrombosis	2.8%
Thrombosis Prophylaxis	2.4%
Type 2 Diabetes Mellitus	2.3%
Pulmonary Arterial Hypertension	2.2%
Prophylaxis	1.9%
Pain	1.8%
Diabetes Mellitus	1.6%
Cardiac Failure Congestive	1.3%
Contraception	1.3%
Stent Placement	1.3%
Cerebrovascular Accident	1.3%
Multiple Myeloma	1.3%

International Normalised Ratio Increased	29.7%
Haemorrhage	6.6%
Gastrointestinal Haemorrhage	6.6%
Thrombosis	6.3%
Vomiting	5.6%
Pulmonary Embolism	4.5%
Subdural Haematoma	4.5%
International Normalised Ratio Decreased	4.5%
Rectal Haemorrhage	4.5%
Epistaxis	3.9%
Weight Decreased	2.9%
Prothrombin Time Prolonged	2.8%
Death	2.6%
Transient Ischaemic Attack	2.4%
International Normalised Ratio Fluctuation	2.3%
Upper Gastrointestinal Haemorrhage	2.2%
Renal Failure Acute	2.1%
Tachycardia	2.1%
Drug Interaction	2.0%
Pneumonia	1.9%

Concomitant

Product Used For Unknown Indication	24.9%
Drug Use For Unknown Indication	17.0%
Pulmonary Arterial Hypertension	11.0%
Hypertension	6.3%
Atrial Fibrillation	5.7%
Multiple Myeloma	4.9%
Pain	4.2%
Osteoporosis	3.1%
Nuclear Magnetic Resonance Imaging	2.5%
Depression	2.3%
Diabetes Mellitus	2.2%
Cardiac Disorder	2.2%
Blood Cholesterol Increased	1.9%
Anticoagulant Therapy	1.9%
Rheumatoid Arthritis	1.8%
Chronic Obstructive Pulmonary Disease	1.7%
Type 2 Diabetes Mellitus	1.7%
Prophylaxis	1.6%
Gastrooesophageal Reflux Disease	1.6%
Pulmonary Hypertension	1.6%

Death	14.0%
Vomiting	10.3%
Weight Decreased	10.1%
Pneumonia	5.9%
Dyspnoea	5.7%
Thrombosis	4.9%
Weight Increased	4.9%
Pulmonary Embolism	4.8%
Urinary Tract Infection	4.5%
Pain	3.6%
Oedema Peripheral	3.5%
Nausea	3.5%
Renal Failure	3.4%
Syncope	3.3%
Vision Blurred	3.2%
International Normalised Ratio Increased	3.1%
Pyrexia	3.0%
Wheezing	2.8%
Myocardial Infarction	2.8%
Rash	2.8%

Interacting

Product Used For Unknown Indication	27.1%
Atrial Fibrillation	14.7%
Drug Use For Unknown Indication	14.7%
Hypertension	4.2%
Thrombosis Prophylaxis	4.2%
Depression	3.7%
Pain	3.7%
Anticoagulant Therapy	3.3%
Prophylaxis	2.8%
Deep Vein Thrombosis	2.4%
Bronchitis	2.3%
Cardiac Disorder	2.2%
Gastrooesophageal Reflux Disease	2.1%
Type 2 Diabetes Mellitus	2.1%
Blood Cholesterol Increased	2.0%
Hypercholesterolaemia	2.0%
Pulmonary Embolism	1.8%
Arrhythmia	1.7%
Insomnia	1.7%
Fungal Infection	1.5%

International Normalised Ratio Increased	36.6%
Drug Interaction	21.3%
International Normalised Ratio Decreased	3.8%
Shock Haemorrhagic	3.4%
Hypocoagulable State	3.0%
Tremor	3.0%
Gastric Haemorrhage	2.6%
International Normalised Ratio Abnormal	2.6%
Prothrombin Time Prolonged	2.6%
Pulmonary Embolism	2.6%
Therapeutic Agent Toxicity	2.6%
Weight Decreased	2.6%
Pulmonary Oedema	2.1%
Gastrointestinal Haemorrhage	1.7%
Gingival Bleeding	1.7%
Haemoptysis	1.7%
Malaise	1.7%
Syncope	1.7%
Thrombosis	1.7%
Haematuria	1.3%